Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the ...
Seattle, USA-based biotech Omeros Corp saw its shares leap 75.5% to $15.36 by close of trading Wednesday, as it revealed that ...
Earlier this month, Omeros Corporation announced that the FDA approved YARTEMLEA (narsoplimab-wuug), the first and only therapy for hematopoietic stem cell transplant-associated thrombotic ...
The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell ...
TA-TMA occurs due to damaged blood vessels during or after a stem cell transplant as a result of an overactive immune system, ...
The Dow Jones Industrial Average climbed 0.6% to 48,731.16, while the S&P 500 added 0.32% to close at 6,932.05.
The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
The U.S. FDA’s green lighting of Omeros Corp.’s Yartemlea (narsoplimab) makes it the first approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...
Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation.
Summary • Omeros Corporation’s stock jumped 72.1% to $15.06 following FDA approval of Yartemlea, its therapy for TA-TMA.• Yartemlea is the first therapy targeting hematopoietic stem cell ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results